Toll Free: 1-888-928-9744

Kidney Fibrosis - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 142 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kidney Fibrosis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Kidney Fibrosis - Pipeline Review, H1 2016', provides an overview of the Kidney Fibrosis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis
- The report reviews pipeline therapeutics for Kidney Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Kidney Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Kidney Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Kidney Fibrosis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Kidney Fibrosis Overview 10 Therapeutics Development 11 Pipeline Products for Kidney Fibrosis - Overview 11 Pipeline Products for Kidney Fibrosis - Comparative Analysis 12 Kidney Fibrosis - Therapeutics under Development by Companies 13 Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes 15 Kidney Fibrosis - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Kidney Fibrosis - Products under Development by Companies 18 Kidney Fibrosis - Products under Investigation by Universities/Institutes 20 Kidney Fibrosis - Companies Involved in Therapeutics Development 21 AbbVie Inc. 21 Angion Biomedica Corp. 22 Bio-inRen 23 BiOrion Technologies B.V. 24 Epigen Biosciences, Inc. 25 Evotec AG 26 Galectin Therapeutics, Inc. 27 GenKyoTex S.A. 28 GNI Group Ltd. 29 Intercept Pharmaceuticals, Inc. 30 Isarna Therapeutics GmbH 31 Lpath, Inc. 32 MorphoSys AG 33 Pharmaxis Limited 34 ProMetic Life Sciences Inc. 35 Raptor Pharmaceutical Corp. 36 Regulus Therapeutics Inc. 37 SciFluor Life Sciences, LLC 38 Symic Biomedical, Inc. 39 Tobira Therapeutics, Inc. 40 Vascular Biogenics Ltd. 41 Kidney Fibrosis - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Target 43 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 ANG-3070 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ANG-3586 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 ANG-4011 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 ANG-4021 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Antisense RNAi Oligonucleotide to Inhibit MicroRNA-21 for Hepatocellular Carcinoma, Kidney Fibrosis and Myocardial Fibrosis - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 BOT-191 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BRN-1889 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 cenicriviroc mesylate - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CT-140 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 cysteamine DR - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Drug to Inhibit Galectin-3 for Fibrosis - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Drugs for Tissue Fibrosis - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 F-351 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 GKT-136901 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 GRMD-02 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 ICG-001 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 INT-767 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 ISTH-0047 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 LJ-1888 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Lpathomab - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 MOR-107 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 P-007 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 PBI-4050 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 PBI-4419 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 PXS-4820 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 PXS-5033A - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 RG-012 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 SB-300 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Small Molecules for Fibrosis - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 SOL-1 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 VB-703 - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 Kidney Fibrosis - Recent Pipeline Updates 106 Kidney Fibrosis - Dormant Projects 134 Kidney Fibrosis - Product Development Milestones 135 Featured News & Press Releases 135 Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics 135 Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting 135 Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 136 Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015 137 Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 138 Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting 138 Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 139 Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 140 Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 140 Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 140 Appendix 141 Methodology 141 Coverage 141 Secondary Research 141 Primary Research 141 Expert Panel Validation 141 Contact Us 141 Disclaimer 142
List of Tables
Number of Products under Development for Kidney Fibrosis, H1 2016 11 Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Development by Companies, H1 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Kidney Fibrosis - Pipeline by AbbVie Inc., H1 2016 21 Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H1 2016 22 Kidney Fibrosis - Pipeline by Bio-inRen, H1 2016 23 Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2016 24 Kidney Fibrosis - Pipeline by Epigen Biosciences, Inc., H1 2016 25 Kidney Fibrosis - Pipeline by Evotec AG, H1 2016 26 Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016 27 Kidney Fibrosis - Pipeline by GenKyoTex S.A., H1 2016 28 Kidney Fibrosis - Pipeline by GNI Group Ltd., H1 2016 29 Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 30 Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2016 31 Kidney Fibrosis - Pipeline by Lpath, Inc., H1 2016 32 Kidney Fibrosis - Pipeline by MorphoSys AG, H1 2016 33 Kidney Fibrosis - Pipeline by Pharmaxis Limited, H1 2016 34 Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2016 35 Kidney Fibrosis - Pipeline by Raptor Pharmaceutical Corp., H1 2016 36 Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc., H1 2016 37 Kidney Fibrosis - Pipeline by SciFluor Life Sciences, LLC, H1 2016 38 Kidney Fibrosis - Pipeline by Symic Biomedical, Inc., H1 2016 39 Kidney Fibrosis - Pipeline by Tobira Therapeutics, Inc., H1 2016 40 Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd., H1 2016 41 Assessment by Monotherapy Products, H1 2016 42 Number of Products by Stage and Target, H1 2016 44 Number of Products by Stage and Mechanism of Action, H1 2016 46 Number of Products by Stage and Route of Administration, H1 2016 48 Number of Products by Stage and Molecule Type, H1 2016 50 Kidney Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016 106 Kidney Fibrosis - Dormant Projects, H1 2016 134


List of Figures
Number of Products under Development for Kidney Fibrosis, H1 2016 11 Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 42 Number of Products by Top 10 Targets, H1 2016 43 Number of Products by Stage and Top 10 Targets, H1 2016 43 Number of Products by Top 10 Mechanism of Actions, H1 2016 45 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45 Number of Products by Routes of Administration, H1 2016 47 Number of Products by Stage and Routes of Administration, H1 2016 47 Number of Products by Top 10 Molecule Types, H1 2016 49 Number of Products by Stage and Top 10 Molecule Types, H1 2016 49

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...

Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energ

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify